CD19-CAR-NK/T therapy(Second Affiliated Hospital, School of Medicine, Zhejiang University)

N/A

Report date: 2025/06/26 20:00:07

Base Information

Drug NameCD19-CAR-NK/T therapy(Second Affiliated Hospital, School of Medicine, Zhejiang University)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesSecond Affiliated Hospital School Of Zhejiang University School Of Medicine

China Registration ClassN/A

Develop Information

Active CompaniesSecond Affiliated Hospital School Of Zhejiang University School Of Medicine

Inactive CompaniesN/A

Active IndicationsLymphoma, Mantle-CellLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A